OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma

What the company announced

OS Therapies reported that its animal health unit, OS Animal Health (OSAH), received feedback from the U.S. Department of Agriculture (USDA) on a regulatory pathway for OST-HER2 in canine osteosarcoma. The company said the USDA provided guidance relevant to a forthcoming conditional licensure request, covering clinical efficacy, clinical safety, non-clinical matters and Chemistry, Manufacturing and Controls (CMC). OS Therapies stated OSAH intends to seek conditional licensure based on clinical efficacy data it has already generated across multiple osteosarcoma settings and expects to run additional clinical studies to pursue full licensure.

Sources: S1

Program and commercial-development details cited

The press release describes OST-HER2 as OSAH's lead candidate for canine osteosarcoma and says OSAH plans to leverage commercial manufacturing work completed by OS Therapies for the human version of OST-HER2. The company reiterated prior regulatory history for OST-HER2, noting it was previously granted a conditional license by the USDA's Center for Veterinary Biologics and that OSAH is seeking a new conditional license based on existing data, to be followed by additional studies intended to support a full license.

Sources: S1

Company-level context and near-term intentions

OS Therapies framed the USDA feedback as part of OSAH's preparation for commercialization and said it is reviewing strategic alternatives to monetize OS Animal Health. The release also states OSAH plans to initiate a crowdfunding in the fourth quarter of 2026 to expand its shareholder base to meet initial listing standards for a U.S. national stock exchange, while cautioning there is no assurance any transaction will occur or be completed as contemplated.

Sources: S1

Why this could matter (inference)

Regulatory alignment and USDA guidance could shape the data and manufacturing commitments OSAH must meet to pursue conditional and eventual full licensure for OST-HER2 in dogs. If OSAH leverages human-program manufacturing progress as stated, that may affect the animal program's CMC pathway and timelines. The company also signals possible structural changes (strategic alternatives and crowdfunding) that it says are intended to support OSAH's commercialization and listing objectives.

Sources: S1

What remains uncertain

• All statements about future regulatory outcomes, commercialization timing, and financing are forward-looking and based on company representations; the USDA feedback described is not an approval and the company notes it expects to run additional studies to gain full licensure.
• The press release is an issuer statement and not independent verification of the USDA's positions or of future approvals, study requirements, manufacturing equivalence between human and animal processes, or the success/timing of any proposed crowdfunding or strategic transaction.